Table 4.
Multivariate analysis of impact factors for ypN+ in breast pathological complete remission patients.
| Factors | OR | 95% CI | p-value |
|---|---|---|---|
| Clinical stage | <0.001 | ||
| cT1-2N0 | 1 | ||
| cT1-2N1 | 5.64 | 2.31–13.76 | <0.001 |
| LABC | 9.80 | 3.88–24.77 | <0.001 |
| PR | 0.036 | ||
| Negative | 1 | ||
| Positive | 1.66 | 1.03–2.67 | |
| HER2 | 0.001 | ||
| Negative | 1 | ||
| Positive | 0.45 | 0.27–0.73 | |
| Molecular subtypes | 0.008 | ||
| Luminal-A like | 1 | ||
| Luminal-B (HER2–) | 0.48 | 0.12–1.85 | 0.286 |
| Luminal-B (HER2+) | 0.20 | 0.05–0.82 | 0.025 |
| HER2-amplified | 0.19 | 0.05–0.83 | 0.026 |
| TNBC | 0.42 | 0.10–1.71 | 0.226 |
| Neoadjuvant targeted therapy | 0.483 | ||
| Yes | 1 | ||
| No | 1.30 | 0.63–2.69 |
CI, confidence interval; HER2, human epidermal growth factor receptor 2; LABC, locally advanced breast cancer; OR, odds ratio; PR, progesterone receptor; TNBC, triple negative breast cancer.